MedicalResearch.com discussion with: Dr. Bertus Eksteen PhD, MBChB, FRCP Founder of the Calgary PSC Clinic Member of the Calgary Liver Unit and the Southern Alberta Liver Transplant Clinic Aspen Woods Clinic Calgary, Canada [caption id="attachment_68489" align="aligncenter" width="500"] Dr. Bertus Eksteen[/caption] Primary sclerosing cholangitis (PSC) is a liver disease characterized by progressive inflammation and scarring of the bile ducts. PSC still has no known cause or cure and often leads to liver failure or cancer. For patients and clinicians, the lack of answers is deeply frustrating. But that's beginning to change. Thanks to genetic research, we’re uncovering clues about PSC’s origins—and why it behaves differently from patient to patient. By learning more about the genomic underpinnings of PSC, researchers can create new treatment targets, devise risk profiles for early diagnosis, and even develop better clinical tools for detecting the disease in its earliest stages.  And that path forward doesn’t just start with new treatments — it begins in the lab.

Genetic Clues to PSC Onset

PSC isn't directly inherited, but genetics likely play a significant role in determining who develops the disease. Several immune-related gene variations, particularly those related to the human leukocyte antigen (HLA) complex, have increased the risks of developing PSC.  These variations don’t cause PSC on their own— researchers believe they interact with intestinal bacteria and other environmental factors, prompting the immune system to launch an attack on the bile ducts. Understanding these genetic foundations provides a roadmap for following this disease very early. Instead of reacting to symptoms, we can start asking why specific people are predisposed in the first place. That insight is key to prevention and long-term disease management.